Browsing by Author Thi, EP

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 10 to 13 of 13 < previous 
TitleAuthor(s)Issue Date
 
Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection
Proceeding/Conference:Hepatology
Yuen, RMFBerliba, EKim, YJHolmes, JALim, YSStrasser, SISchwabe, CJucov, ALee, ACHThi, EPHarasym, TPamulapati, GRWattamwar, PKunta, JSofia, MJSevinsky, HGray, KEley, TPicchio, GRSims, KGane, EJ
2020
 
Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B
Journal:Hepatology Communications
Yuen, MFBerliba, ESukeepaisarnjaroen, WAhn, SHTanwandee, TLim, YSKim, YJPoovorawan, KTangkijvanich, PSchwabe, CEley, TBrown, JLee, ACHThi, EPParatala, BMani, NSofia, MJPicchio, GSims, KDGane, EJ
4-Oct-2022
 
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects(HS) and subjects with chronic hepatitis B (CHB). Poster Presentation (SAT392)
Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology
Gane, EJJucov, AKolomiichuk, LEley, TBrown, JKing, YMedvedeva, EChernyakhovskyy, MMani, NCole, AGKultgen, SGPamulapati, RThi, EPHarasym, TODugyala, RChaudhari, SSofia, MJChild, MPicchio, GSims, KYuen, RMF
2022
 
Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the capsid inhibitor (CI) AB-506 in healthy subjects (HS) and chronic hepatitis B (CHB) subjects
Proceeding/Conference:Hepatology
Yuen, RMFBerliba, ESukeepaisarnjaroen, WAhn, SHTanwandee, TLim, Y-SKim, YJPoovorawan, KTangkijvanich, PChan, HLYEley, TBrown, JMoore, CLee, ACHKim, JThi, EPMani, NRijnbrand, RCole, ASofia, MJPicchio, GRSims, KGane, EJ
2019
Showing results 10 to 13 of 13 < previous